Kappa Free Light Chains in Multiple Sclerosis as a Marker of Intrathecal Humoral Response: A Sex-Disaggregated Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Study Population
2.3. Sampling
2.4. Quantitative Analyses
2.5. Qualitative Analyses
2.6. Statistical Analysis
3. Results
3.1. Cerebrospinal Fluid, Serum, and Quantitative Indices of Albumin, IgG, and KFLCs in Sex-Disaggregated Multiple Sclerosis Patients and Controls
3.2. Positivity of Quantitative Indices of Albumin, IgG, and KFLCs in Sex-Disaggregated Multiple Sclerosis Patients and Controls
3.3. The Ability of KFLC Indices and IgG Oligoclonal Bands to Identify the Diagnosis of Multiple Sclerosis
3.4. Cerebrospinal Fluid, Serum, and Quantitative Indices of Albumin, IgG, and KFLCs for Sex-Disaggregated Patients Grouped by OCB Positivity
3.5. Positivity of Quantitative Indices of Albumin, IgG, and KFLC for Sex-Disaggregated Patients Grouped by OCB Positivity
3.6. Inter-Rater Reliability of KFLC Indices and IgG Oligoclonal Bands
3.7. No-Multiple-Sclerosis and CSF-Restricted OCB-Negative Subjects Positive for KFLCs
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gastaldi, M.; Zardini, E.; Franciotta, D. An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. Expert Rev. Mol. Diagn. 2017, 17, 31–46. [Google Scholar] [CrossRef] [PubMed]
- Andersson, M.; Alvarez-Cermeno, J.; Bernardi, G.; Cogato, I.; Fredman, P.; Frederiksen, J.; Fredrikson, S.; Gallo, P.; Grimaldi, L.M.; Gronning, M.; et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J. Neurol. Neurosurg. Psychiatry 1994, 57, 897–902. [Google Scholar] [PubMed]
- Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17, 162–173. [Google Scholar] [CrossRef] [PubMed]
- Uccelli, A.; Aloisi, F.; Pistoia, V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 2005, 26, 254–259. [Google Scholar] [CrossRef]
- Lamers, K.J.; de Jong, J.G.; Jongen, P.J.; Kock-Jansen, M.J.; Teunesen, M.A.; Prudon-Rosmulder, E.M. Cerebrospinal fluid free kappa light chains versus IgG findings in neurological disorders: Qualitative and quantitative measurements. J. Neuroimmunol. 1995, 62, 19–25. [Google Scholar] [CrossRef] [PubMed]
- Leurs, C.E.; Twaalfhoven, H.; Lissenberg-Witte, B.I.; van Pesch, V.; Dujmovic, I.; Drulovic, J.; Castellazzi, M.; Bellini, T.; Pugliatti, M.; Kuhle, J.; et al. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult. Scler. 2020, 26, 912–923. [Google Scholar] [CrossRef] [PubMed]
- Hegen, H.; Berek, K.; Deisenhammer, F. Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity. Wien. Med. Wochenschr. 2022, 172, 337–345. [Google Scholar] [CrossRef]
- Presslauer, S.; Milosavljevic, D.; Huebl, W.; Aboulenein-Djamshidian, F.; Krugluger, W.; Deisenhammer, F.; Senel, M.; Tumani, H.; Hegen, H. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Mult. Scler. 2016, 22, 502–510. [Google Scholar] [CrossRef]
- Reiber, H. Flow rate of cerebrospinal fluid (CSF)—A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 1994, 122, 189–203. [Google Scholar] [CrossRef] [PubMed]
- Candeloro, R.; Ferri, C.; Bellini, T.; Pugliatti, M.; Castellazzi, M. Breaking Barriers: Unveiling Sex-Related Differences in Cerebrospinal Fluid Analysis-A Narrative Review. Biology 2024, 13, 420. [Google Scholar] [CrossRef]
- Schiffer, E.; Van Gessel, E.; Gamulin, Z. Influence of sex on cerebrospinal fluid density in adults. Br. J. Anaesth. 1999, 83, 943–944. [Google Scholar] [CrossRef] [PubMed]
- Castellazzi, M.; Morotti, A.; Tamborino, C.; Alessi, F.; Pilotto, S.; Baldi, E.; Caniatti, L.M.; Trentini, A.; Casetta, I.; Granieri, E.; et al. Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient. Fluids Barriers CNS 2020, 17, 14. [Google Scholar] [CrossRef]
- Verde, F.; Ferrari, I.; Maranzano, A.; Ciusani, E.; Torre, S.; Milone, I.; Colombo, E.; Doretti, A.; Peverelli, S.; Ratti, A.; et al. Relationship between cerebrospinal fluid/serum albumin quotient and phenotype in amyotrophic lateral sclerosis: A retrospective study on 328 patients. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2023, 44, 1679–1685. [Google Scholar] [CrossRef] [PubMed]
- Meixensberger, S.; Bechter, K.; Dersch, R.; Feige, B.; Maier, S.; Schiele, M.A.; Runge, K.; Denzel, D.; Nickel, K.; Spieler, D.; et al. Sex difference in cerebrospinal fluid/blood albumin quotients in patients with schizophreniform and affective psychosis. Fluids Barriers CNS 2020, 17, 67. [Google Scholar] [CrossRef]
- Parrado-Fernandez, C.; Blennow, K.; Hansson, M.; Leoni, V.; Cedazo-Minguez, A.; Bjorkhem, I. Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers. J. Cell Mol. Med. 2018, 22, 5151–5154. [Google Scholar] [CrossRef]
- Teunissen, C.; Menge, T.; Altintas, A.; Alvarez-Cermeno, J.C.; Bertolotto, A.; Berven, F.S.; Brundin, L.; Comabella, M.; Degn, M.; Deisenhammer, F.; et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult. Scler. 2013, 19, 1802–1809. [Google Scholar] [CrossRef]
- Reiber, H.; Otto, M.; Trendelenburg, C.; Wormek, A. Reporting cerebrospinal fluid data: Knowledge base and interpretation software. Clin. Chem. Lab. Med. 2001, 39, 324–332. [Google Scholar] [CrossRef] [PubMed]
- Hegen, H.; Auer, M.; Zeileis, A.; Deisenhammer, F. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: Implications for increased clinical specificity. Clin. Chem. Lab. Med. 2016, 54, 285–292. [Google Scholar] [CrossRef] [PubMed]
- Ferraro, D.; Bedin, R.; Natali, P.; Franciotta, D.; Smolik, K.; Santangelo, M.; Immovilli, P.; Camera, V.; Vitetta, F.; Gastaldi, M.; et al. Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders. Diagnostics 2020, 10, 856. [Google Scholar] [CrossRef] [PubMed]
- Menéndez-Valladares, P.; García-Sánchez, M.I.; Adorna Martínez, M.; García De Veas Silva, J.L.; Bermudo Guitarte, C.; Izquierdo Ayuso, G. Validation and meta-analysis of kappa index biomarker in multiple sclerosis diagnosis. Autoimmun. Rev. 2019, 18, 43–49. [Google Scholar] [CrossRef] [PubMed]
- Schwenkenbecher, P.; Konen, F.F.; Wurster, U.; Witte, T.; Gingele, S.; Sühs, K.W.; Stangel, M.; Skripuletz, T. Reiber’s Diagram for Kappa Free Light Chains: The New Standard for Assessing Intrathecal Synthesis? Diagnostics 2019, 9, 194. [Google Scholar] [CrossRef] [PubMed]
- Castellazzi, M.; Ferri, C.; Alfiero, S.; Lombardo, I.; Laudisi, M.; Tecilla, G.; Boni, M.; Pizzicotti, S.; Fainardi, E.; Bellini, T.; et al. Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients. Diagnostics 2021, 11, 884. [Google Scholar] [CrossRef] [PubMed]
- Landis, J.R.; Koch, G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33, 159–174. [Google Scholar] [CrossRef] [PubMed]
- Monreal, E.; Fernández-Velasco, J.I.; García-Soidán, A.; Sainz de la Maza, S.; Espiño, M.; Villarrubia, N.; Rodríguez-Jorge, F.; Chico-García, J.L.; Sainz-Amo, R.; Masjuan, J.; et al. Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis. Front. Immunol. 2023, 14, 1288169. [Google Scholar] [CrossRef] [PubMed]
- Hegen, H.; Walde, J.; Berek, K.; Arrambide, G.; Gnanapavan, S.; Kaplan, B.; Khalil, M.; Saadeh, R.; Teunissen, C.; Tumani, H.; et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Mult. Scler. 2023, 29, 169–181. [Google Scholar] [CrossRef] [PubMed]
- Reiber, H.; Zeman, D.; Kušnierová, P.; Mundwiler, E.; Bernasconi, L. Diagnostic relevance of free light chains in cerebrospinal fluid—The hyperbolic reference range for reliable data interpretation in quotient diagrams. Clin. Chim. Acta Int. J. Clin. Chem. 2019, 497, 153–162. [Google Scholar] [CrossRef] [PubMed]
Males | Females | p | |
---|---|---|---|
MS patients: n | 43 | 106 | |
CSF albumin (mg/L): median (IQR) | 252.2 (191.1–341.1) | 189.0 (142.5–254.5) | 0.0005 |
Serum albumin (g/L): median (IQR) | 48.40 (45.65–51.49) | 43.7 (40.78–47.93) | 0.0004 |
QAlb × 10−3: median (IQR) | 5.5 (3.8–7.5) | 4.535 (3.403–5.640) | 0.0130 |
CSF IgG (mg/L): median (IQR) | 41.70 (26.40–60.40) | 34.75 (25.25–52.68) | 0.2899 |
Serum IgG (g/L): median (IQR) | 10.09 (8.904–12.14) | 10.45 (9.1–12.43) | 0.2338 |
IgG Index: median (IQR) | 0.6780 (0.551–0.858) | 0.715 (0.5775–0.9175) | 0.4329 |
CSF KFLC (mg/L): median (IQR) | 2.050 (0.77–3.830) | 1.715 (0.7775–5.295) | 0.9127 |
Serum KFLC (mg/L): median (IQR) | 12.74 (10.02–16.12) | 14.17 (10.31–17.17) | 0.3435 |
K Index: median (IQR) | 24.80 (8.0–84.20) | 27.75 (13.28–80.08) | 0.8501 |
OND patients: n | 40 | 44 | |
CSF albumin (mg/L): median (IQR) | 291.0 (247.3–374.5) | 274.0 (230.5–329.5) | 0.2892 |
Serum albumin (g/L): median (IQR) | 45.09 (37.77–48.48) | 42.40 (37.70–47.73) | 0.4418 |
QAlb × 10−3: median (IQR) | 6.62 (5.268–9.460) | 6.660 (5.220–7.863) | 0.3523 |
CSF IgG (mg/L): median (IQR) | 37.5 (29.45–68.35) | 41.35 (25.53–68.43) | 0.7232 |
Serum IgG (g/L): median (IQR) | 11.07 (9.342–12.97) | 10.75 (9.20–12.75) | 0.7199 |
IgG Index: median (IQR) | 0.5500 (0.4425–0.6335) | 0.565 (0.472–0.680) | 0.3251 |
CSF KFLC (mg/L): median (IQR) | 0.505 (0.2825–1.205) | 0.540 (0.000–2.158) | 0.7913 |
Serum KFLC (mg/L): median (IQR) | 19.39 (13.89–34.67) | 14.88 (11.34–21.23) | 0.0150 |
K Index: median (IQR) | 1.350 (0.8250–13.13) | 5.40 (0.000–14.55) | 0.7292 |
Males | Females | p | |
---|---|---|---|
MS patients: n | 43 | 106 | |
QAlb > age/15 + 4: n (%) | 15 (34.9%) | 15 (14.2%) | 0.0065 |
QAlb > age/25 + 8: n (%) | 6 (14%) | 4 (3.8%) | 0.0342 |
IgG Index > 0.7: n (%) | 19 (44.2%) | 56 (52.8%) | 0.3700 |
K Index > 5.9: n (%) | 34 (79.1%) | 90 (84.9%) | 0.4684 |
K Index > 6.1: n (%) | 34 (79.1%) | 90 (84.9%) | 0.4684 |
K Index > 6.61: n (%) | 34 (79.1%) | 89 (83.9%) | 0.4822 |
K Index > 10.61: n (%) | 32 (74.41%) | 85 (80.18%) | 0.5098 |
QKFLCLOC > 0: n (%) | 40 (93.0%) | 93 (87.73%) | 0.5595 |
Intrathecal IgG OCB: n (%): | 30 (69.8%) | 78 (73.6%) | 0.6873 |
OND patients: n | 40 | 44 | |
QAlb > age/15 + 4: n (%) | 13 (32.5%) | 22 (50%) | 0.1245 |
QAlb > age/25 + 8: n (%) | 8 (20%) | 8 (18.18%) | >0.9999 |
IgG Index > 0.7: n (%) | 7 (17.50%) | 10 (22.73%) | 0.5969 |
K Index > 5.9: n (%) | 11 (27.5%) | 22 (50%) | 0.0451 |
K Index > 6.1: n (%) | 11 (27.5%) | 21 (47.7%) | 0.0732 |
K Index > 6.61: n (%) | 11 (27.5%) | 20 (45.45%) | 0.1145 |
K Index > 10.61: n (%) | 11 (27.5%) | 18 (40.9%) | 0.2524 |
QKFLCLOC > 0: n (%) | 19 (47.5%) | 24 (54.55%) | 0.6624 |
Intrathecal IgG OCB: n (%): | 7 (17.50%) | 16 (36.36%) | 0.0853 |
Males | Females | p | |
---|---|---|---|
OCB+: n | 37 | 94 | |
CSF albumin (mg/L): median (IQR) | 245.8 (193.3–328.7) | 229.5 (153.3–282.5) | 0.0317 |
Serum albumin (g/L): median (IQR) | 48.4 (44.25–50.55) | 44.3 (40.1–48.13) | 0.0035 |
QAlb × 10−3: median (IQR) | 5.21 (3.925–7.225) | 4.915 (3.588–6.128) | 0.1726 |
CSF IgG (mg/L): median (IQR) | 43.6 (29.95–61.75) | 42.1 (28.6–59.48) | 0.8397 |
Serum IgG (g/L): median (IQR) | 9.905 (8.919–11.79) | 10.55 (9.4–12.9) | 0.0716 |
IgG Index: median (IQR) | 0.734 (0.61–1.025) | 0.75 (0.61–1.033) | 0.6941 |
CSF KFLC (mg/L): median (IQR) | 2.51 (1.545–4.765) | 2.325 (1.085–7.333) | 0.8417 |
Serum KFLC (mg/L): median (IQR) | 13.41 (10.25–15.5) | 14.68 (10.64–17.43) | 0.1390 |
K Index: median (IQR) | 33.2 (22.35–85.15) | 40.05 (15.78–92.03) | 0.9179 |
OCB−: n | 46 | 56 | |
CSF albumin (mg/L): median (IQR) | 287.2 (249.2–391.0) | 245.0 (162.8–292.8) | 0.0008 |
Serum albumin (g/L): median (IQR) | 45.93 (38.67–49.18) | 43.5 (40.23–46.65) | 0.4262 |
QAlb × 10−3: median (IQR) | 6.595 (5.228–10.07) | 5.38 (3.638–7.25) | 0.0019 |
CSF IgG (mg/L): median (IQR) | 36.55 (26.58–67.45) | 27.35 (19.05–47.78) | 0.0096 |
Serum IgG (g/L): median (IQR) | 10.87 (9.287–13.05) | 10.45 (8.85–12.28) | 0.2619 |
IgG Index: median (IQR) | 0.52 (0.44–0.606) | 0.52 (0.4625–0.6075) | 0.5633 |
CSF KFLC (mg/L): median (IQR) | 0.465 (0.0–0.765) | 0.37 (0.0–0.86) | 0.4008 |
Serum KFLC (mg/L): median (IQR) | 18.58 (12.39–29.34) | 14.01 (10.56–19.34) | 0.0052 |
K Index: median (IQR) | 1.35 (0.0–6.2) | 1.45 (0.0–14.38) | 0.7655 |
Males | Females | p | |
---|---|---|---|
OCB+: n | 37 | 94 | |
QAlb > age/15 + 4: n (%) | 12 (32.4) | 17 (18.1) | 0.1011 |
QAlb > age/25 + 8: n (%) | 3 (8.1) | 6 (6.4) | 0.7116 |
IgG Index > 0.7: n (%) | 21 (56.8) | 57 (60.6) | 0.6970 |
K Index > 5.9: n (%) | 34 (91.9) | 89 (94.7) | 0.6865 |
K Index > 6.1: n (%) | 34 (91.9) | 88 (93.6) | 0.7116 |
K Index > 6.61: n (%) | 34 (91.9) | 86 (91.5) | >0.9999 |
K Index > 10.61: n (%) | 34 (91.9) | 84 (89.4) | >0.9999 |
QKFLCLOC > 0: n (%) | 37 (100) | 91 (96.8) | 0.5583 |
OCB−: n | 46 | 56 | |
QAlb > age/15 + 4: n (%) | 16 (34.8) | 13 (23.2) | 0.2702 |
QAlb > age/25 + 8: n (%) | 11 (23.9) | 6 (10.7) | 0.1086 |
IgG Index > 0.7: n (%) | 5 (10.9) | 6 (10.7) | >0.9999 |
K Index > 5.9: n (%) | 11 (23.9) | 23 (41.1) | 0.0914 |
K Index > 6.1: n (%) | 11 (23.9) | 23 (41.1) | 0.0914 |
K Index > 6.61: n (%) | 11 (23.9) | 23 (41.1) | 0.0914 |
K Index > 10.61: n (%) | 9 (19.6) | 19 (33.9) | 0.1230 |
QKFLCLOC > 0: n (%) | 22 (47.8) | 26 (46.4) | >0.9999 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Candeloro, R.; Galloppa, M.; Lombardo, L.; Laudisi, M.; Ghisellini, S.; Negri, G.; Ferri, C.; Marcialis, C.; Bellini, T.; Pugliatti, M.; et al. Kappa Free Light Chains in Multiple Sclerosis as a Marker of Intrathecal Humoral Response: A Sex-Disaggregated Study. Diagnostics 2024, 14, 2798. https://doi.org/10.3390/diagnostics14242798
Candeloro R, Galloppa M, Lombardo L, Laudisi M, Ghisellini S, Negri G, Ferri C, Marcialis C, Bellini T, Pugliatti M, et al. Kappa Free Light Chains in Multiple Sclerosis as a Marker of Intrathecal Humoral Response: A Sex-Disaggregated Study. Diagnostics. 2024; 14(24):2798. https://doi.org/10.3390/diagnostics14242798
Chicago/Turabian StyleCandeloro, Raffaella, Maila Galloppa, Laura Lombardo, Michele Laudisi, Sara Ghisellini, Giovanna Negri, Caterina Ferri, Carla Marcialis, Tiziana Bellini, Maura Pugliatti, and et al. 2024. "Kappa Free Light Chains in Multiple Sclerosis as a Marker of Intrathecal Humoral Response: A Sex-Disaggregated Study" Diagnostics 14, no. 24: 2798. https://doi.org/10.3390/diagnostics14242798
APA StyleCandeloro, R., Galloppa, M., Lombardo, L., Laudisi, M., Ghisellini, S., Negri, G., Ferri, C., Marcialis, C., Bellini, T., Pugliatti, M., & Castellazzi, M. (2024). Kappa Free Light Chains in Multiple Sclerosis as a Marker of Intrathecal Humoral Response: A Sex-Disaggregated Study. Diagnostics, 14(24), 2798. https://doi.org/10.3390/diagnostics14242798